SCHEMBL20128969

SCHEMBL20128969

CCCCCCOCCCCCOC1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.43
CES2 O00748 2/20 0.41
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
GPR119 Q8TDV5 4/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
SPHK1 Q9NYA1 1/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
HPGD P15428 1/20 0.36
GBA2 Q9HCG7 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26048944 0.94 NR1H2 (0.47) NR1H2PRMT5WDR77GPR119PDE4A
SCHEMBL27097799 0.93 NR1H2 (0.43) NR1H2PRMT5WDR77GPR119PDE4A
SCHEMBL20129034 0.93 NR1H2 (0.43) NR1H2PRMT5WDR77GPR119PDE4A
SCHEMBL26495742 0.90 NR1H2 (0.43) NR1H2PRMT5WDR77GPR119PDE4A
SCHEMBL27097864 0.90 NR1H2 (0.43) NR1H2PRMT5WDR77GPR119PDE4A
SCHEMBL20129252 0.90 NR1H2 (0.43) NR1H2PRMT5WDR77GPR119PDE4A
SCHEMBL20129179 0.90 NR1H2 (0.48) NR1H2PRMT5WDR77GPR119PDE4A
SCHEMBL20128966 0.89 NR1H2 (0.46) NR1H2PRMT5WDR77GPR119PDE4B
SCHEMBL20129254 0.85 NR1H2 (0.47) NR1H2PRMT5WDR77GPR119PDE4B
SCHEMBL20129035 0.85 NR1H2 (0.47) NR1H2PRMT5WDR77GPR119PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN NR1H2 3409/4885CES2 3979/4885PRMT5 584/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 NR1H2 3751/4885CES2 3829/4885PRMT5 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.